Stephanie S. Okey, M.S.
Former SVP, Head of North America, Rare Disease - Genzyme
Ms. Okey has over 30 years’ experience in the biopharmaceutical industry. She most recently served as the Senior Vice President, Head of North America, Rare Diseases and U.S. General Manager, Rare Diseases at Genzyme, A Sanofi Company. Ms. Okey has significant experience in pre-launch, launch and commercialization of rare and orphan disease products, as well as large market products. During her time at Genzyme, Ms. Okey oversaw 500 employees and was responsible for six business units: Gaucher Disease and MPS1, Fabry Disease, Pompe and Neuromuscular Diseases, Cardiovascular Diseases, Endocrine Diseases and Leukine and Immunologic Diseases, totaling revenue responsibility > 1B US$. She has successfully launched 13 therapeutic agents, 9 of which were in the orphan disease space and two with REMS designation. Ms. Okey is highly knowledgeable about complex approval processes, healthcare stakeholder systems and creation of high growth markets. Ms. Okey holds extensive experience in the commercialization of orphan disease products in a patient centric business model. Prior to her 19-year tenure at Genzyme, Ms. Okey held roles at Bristol-Myers Squibb and Genentech, Inc.
Ms. Okey has served as a member of PTC’s board of directors since December 2018. She also serves on the board of directors of Albireo Pharma, Inc., Crinetics Pharmaceuticals and Orphazyme. In addition, she previously served as a member of the board of directors of the California Life Sciences Association from October 2014 to January 2016. Ms. Okey holds a B.S. in Zoology from The Ohio State University and an M.S. in Immunology and Medical Microbiology from Wright State University.